Dyne Therapeutics Announces Positive One-Year Phase 1/2 Data for Zeleciment Basivarsen Demonstrating Functional Improvement in Myotonic Dystrophy Type 1
Dyne Therapeutics Inc. announced additional one-year data from its ongoing Phase 1/2 ACHIEVE clinical trial evaluating zeleciment basivarsen (formerly DYNE-101) in patients with myotonic dystrophy type 1 (DM1). The results demonstrated clinically meaningful improvements in function and strength at the selected registrational dose, with both patients and physicians reporting reductions in overall disease burden. These findings were presented at the 30th Annual International Congress of the World Muscle Society $(WMS)$, held virtually and in Vienna, Austria, from October 7-11, 2025. Poster presentations and symposium materials are available on Dyne's website in the Scientific Publications & Presentations section.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9540973-en) on October 06, 2025, and is solely responsible for the information contained therein.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。